MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Checkpoint Therapeutics Inc

Închisă

SectorSănătate

4.03 -0.25

Rezumat

Modificarea prețului

24h

Curent

Minim

3.98

Maxim

4.04

Indicatori cheie

By Trading Economics

Angajați

23

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+31.19% upside

Dividende

By Dow Jones

Următoarele câștiguri

9 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

207M

Deschiderea anterioară

4.28

Închiderea anterioară

4.03

Sentimentul știrilor

By Acuity

50%

50%

180 / 386 Clasament în Healthcare

Checkpoint Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 mar. 2025, 10:23 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma

14 dec. 2024, 00:24 UTC

Principalele dinamici ale pieței

Checkpoint Therapeutics' Shares Rise After Securing First FDA Approval

25 iul. 2024, 13:02 UTC

Principalele dinamici ale pieței

Checkpoint Therapeutics Shares Rise After FDA Accepts Resubmission of Cosibelimab

10 mar. 2025, 02:12 UTC

Achiziții, Fuziuni, Preluări

Checkpoint Controlling Shareholder Fortress Has Agreed to Vote in Favor of Transaction >524715.BY

10 mar. 2025, 02:12 UTC

Achiziții, Fuziuni, Preluări

Sun Pharma, Checkpoint Transaction Expected to Complete in 2Q 2025 >524715.BY

10 mar. 2025, 02:11 UTC

Achiziții, Fuziuni, Preluări

Sun Pharma, Checkpoint, Fortress Biotech Enter Into Royalty Agreement >524715.BY

10 mar. 2025, 02:11 UTC

Achiziții, Fuziuni, Preluări

Checkpoint Shareholders Entitled to Receive Up to Additional $0.70 if Cosibelimab if Approved in EU Prior to Certain Deadlines >524715.BY

10 mar. 2025, 02:10 UTC

Achiziții, Fuziuni, Preluări

Checkpoint Shareholders to Receive Upfront Cash Payment of $4.10/Share, Contingent Value Right >524715.BY

10 mar. 2025, 02:10 UTC

Achiziții, Fuziuni, Preluări

Sun Pharma to Acquire Checkpoint Therapeutics >524715.BY CKPT

10 mar. 2025, 02:06 UTC

Achiziții, Fuziuni, Preluări

Sun Pharma To Acquire Checkpoint Therapeutics >524715.BY CKPT

Comparație

Modificare preț

Checkpoint Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

31.19% sus

Prognoză pe 12 luni

Medie 5.3 USD  31.19%

Maxim 7 USD

Minim 4.1 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCheckpoint Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

3 ratings

1

Cumpărare

2

Păstrare

0

Vânzare

Sentiment

By Acuity

180 / 386 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

$

Despre Checkpoint Therapeutics Inc

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with GC Cell. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.